Coiled Therapeutics PLC
10 August 2026
10 August 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Change of Registered Office
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that, with immediate effect, the registered office of the Company has changed to 167-169 Great Portland Street, 5th Floor, London W1W 5PF, United Kingdom.
-Ends-
Enquiries:
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO) |
Via Burson Buchanan |
|
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
+44 (0)20 3470 0470 |
|
Shard Capital Partners LLP (Joint Broker) Damon Heath
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino |
+44 (0)20 4530 6926 +61 (0)8 9223 2222 |
|
Burson Buchanan (Public Relations) Henry Harrison Topham / Jamie Hooper / Toto Berger |
+44 (0)20 7466 5000 |
|
|
|
|
Harbor Access (US Investor Relations) Matt Kelly / Jonathan Paterson |
+1 475 477 9404 |
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in a Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy is designed to generate the clinical evidence sought by potential pharmaceutical partners in selected tumour types, including ovarian and prostate cancer, while advancing a broader pipeline that includes a STAT6 siRNA programme for immunology indications.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.
By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.
AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study. The Company plans to initiate Phase I/II dose-expansion cohorts in ovarian and prostate cancer in H2 2026.
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.